Search Results - "Collins, Taylor B."

Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling by Fisher, Daniel A. C., Miner, Cathrine A., Engle, Elizabeth K., Hu, Hengrui, Collins, Taylor B., Zhou, Amy, Allen, Maggie J., Malkova, Olga N., Oh, Stephen T.

“…The distinct clinical features of myelofibrosis (MF) have been attributed in part to dysregulated inflammatory cytokine production. Circulating cytokine levels…”
Get full text

Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms by Collins, Taylor B., Laranjeira, Angelo B.A., Kong, Tim, Fulbright, Mary C., Fisher, Daniel A.C., Sturgeon, Christopher M., Batista, Luis F.Z., Oh, Stephen T.

“…•JAK2 and ASXL1 mutations inflict opposing regulation of erythropoiesis.•Mutant ASXL1 upregulates PRMT6.•PRMT6 inhibition specifically augments disease burden…”
Get full text

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition by Kong, Tim, Laranjeira, Angelo B.A., Collins, Taylor B., De Togni, Elisa S., Wong, Abigail J., Fulbright, Mary C., Ruzinova, Marianna, Celik, Hamza, Challen, Grant A., Fisher, Daniel A.C., Oh, Stephen T.

“…Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone persists…”
Get full text

Interrogating the Role of ASXL1 and JAK2 mutations in Myeloproliferative Neoplasms Utilizing Human Pluripotent Stem Cells by Collins, Taylor B., Luff, Stephanie A., Batista, Luis F.Z., Sturgeon, Christopher M., Oh, Stephen T.

“…JAK2 V617F is the most frequent mutation found in myeloproliferative neoplasms (MPNs), with 50-60% of myelofibrosis (MF) patients harboring this mutation…”
Get full text

Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia by Fisher, D A C, Malkova, O, Engle, E K, Miner, C A, Fulbright, M C, Behbehani, G K, Collins, T B, Bandyopadhyay, S, Zhou, A, Nolan, G P, Oh, S T

“…Myeloproliferative neoplasms (MPNs) feature a malignant clone containing the JAK2 V617F mutation, or another mutation causing dysregulated JAK2 kinase…”
Get full text

Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NF[kappa]B signaling by Fisher, Daniel A. C, Miner, Cathrine A, Engle, Elizabeth K, Hu, Hengrui, Collins, Taylor B, Zhou, Amy, Allen, Maggie J

“…The distinct clinical features of myelofibrosis (MF) have been attributed in part to dysregulated inflammatory cytokine production. Circulating cytokine levels…”
Get full text

Mass Cytometry Analysis Reveals Cellular Loci of Cytokine Overproduction in Myelofibrosis with Differential Sensitivity to Ruxolitinib by Fisher, Daniel A.C., Miner, Cathrine, Engle, Elizabeth, Collins, Taylor B., Hu, Hengrui, Malkova, Olga, Oh, Stephen

“…Inflammatory cytokine production is a characteristic feature of myeloproliferative neoplasms including myelofibrosis (MF). Inhibition of JAK2 with ruxolitinib…”
Get full text

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling by Fisher, Daniel A.C., Miner, Cathrine, Engle, Elizabeth, Hu, Hengrui, Collins, Taylor B., Zhou, Amy, Allen, Maggie J., Malkova, Olga, Oh, Stephen T

“…Inflammatory cytokine production is characteristic of myeloproliferative neoplasms including myelofibrosis (MF). Clonal dominance and bone marrow fibrosis have…”
Get full text